DE1617545C2 - Verwendung von informatorischer Ribonucleinsäure als Vaccine - Google Patents
Verwendung von informatorischer Ribonucleinsäure als VaccineInfo
- Publication number
- DE1617545C2 DE1617545C2 DE1617545A DE1617545A DE1617545C2 DE 1617545 C2 DE1617545 C2 DE 1617545C2 DE 1617545 A DE1617545 A DE 1617545A DE 1617545 A DE1617545 A DE 1617545A DE 1617545 C2 DE1617545 C2 DE 1617545C2
- Authority
- DE
- Germany
- Prior art keywords
- informational
- vaccine
- cell
- antigen
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title claims description 34
- 229920002477 rna polymer Polymers 0.000 title claims description 32
- 210000004027 cell Anatomy 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 210000004671 cell-free system Anatomy 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 241000589562 Brucella Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009800 post vaccination immunity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEJ0033936 | 1967-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE1617545A1 DE1617545A1 (de) | 1971-04-01 |
| DE1617545C2 true DE1617545C2 (de) | 1983-11-03 |
Family
ID=7204943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1617545A Expired DE1617545C2 (de) | 1967-06-19 | 1967-06-19 | Verwendung von informatorischer Ribonucleinsäure als Vaccine |
Country Status (13)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3115559A1 (de) * | 1981-04-16 | 1982-10-28 | Kommanditgesellschaft Schwarzhaupt, 5000 Köln | Hochgereinigte informatorische ribonukleinsaeure (i-rns), verfahren zur herstellung und verwendung derselben |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE754934A (fr) * | 1969-08-16 | 1971-02-17 | Jachertz Diether | Procede de production enzymatique d'arn-messager |
| GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
| GB2216416B (en) * | 1988-03-11 | 1992-06-24 | Sandoz Ltd | Nucleobase source for the stimulation of the immune system |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
-
1967
- 1967-06-19 DE DE1617545A patent/DE1617545C2/de not_active Expired
-
1968
- 1968-06-12 IL IL30168A patent/IL30168A/en unknown
- 1968-06-15 NO NO2340/68A patent/NO124840B/no unknown
- 1968-06-17 CH CH893668A patent/CH513241A/de not_active IP Right Cessation
- 1968-06-17 IE IE713/68A patent/IE32140B1/xx unknown
- 1968-06-17 NL NL6808486A patent/NL6808486A/xx unknown
- 1968-06-17 AT AT576668A patent/AT282821B/de not_active IP Right Cessation
- 1968-06-18 DK DK286268AA patent/DK119724B/da unknown
- 1968-06-18 ES ES355121A patent/ES355121A1/es not_active Expired
- 1968-06-19 BE BE716806D patent/BE716806A/xx unknown
- 1968-06-19 FR FR1588820D patent/FR1588820A/fr not_active Expired
- 1968-06-19 GB GB1229888D patent/GB1229888A/en not_active Expired
- 1968-06-19 BR BR199970/68A patent/BR6899970D0/pt unknown
- 1968-09-18 FR FR166589A patent/FR7781M/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3115559A1 (de) * | 1981-04-16 | 1982-10-28 | Kommanditgesellschaft Schwarzhaupt, 5000 Köln | Hochgereinigte informatorische ribonukleinsaeure (i-rns), verfahren zur herstellung und verwendung derselben |
Also Published As
| Publication number | Publication date |
|---|---|
| BE716806A (enrdf_load_stackoverflow) | 1968-12-19 |
| NL6808486A (enrdf_load_stackoverflow) | 1968-12-20 |
| ES355121A1 (es) | 1969-11-16 |
| DE1617545A1 (de) | 1971-04-01 |
| CH513241A (de) | 1971-09-30 |
| IL30168A (en) | 1973-05-31 |
| NO124840B (enrdf_load_stackoverflow) | 1972-06-12 |
| FR1588820A (enrdf_load_stackoverflow) | 1970-03-16 |
| DK119724B (da) | 1971-02-15 |
| IE32140L (en) | 1968-12-19 |
| AT282821B (de) | 1970-07-10 |
| FR7781M (enrdf_load_stackoverflow) | 1970-03-23 |
| IE32140B1 (en) | 1973-04-18 |
| GB1229888A (enrdf_load_stackoverflow) | 1971-04-28 |
| BR6899970D0 (pt) | 1973-02-13 |
| IL30168A0 (en) | 1968-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT408615B (de) | Neue influenzavirus-impfstoffzusammensetzung | |
| DE3911442C2 (de) | Impfstoff-Präparation | |
| DE69732407T3 (de) | Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren | |
| DE69334066T2 (de) | Impfstoffzusammensetzungen für mukosale Abgabe | |
| WO1989007946A1 (en) | Virally modified tumour vaccines for immunotherapy of tumour metastases | |
| EP0304786A2 (de) | Intranasale Impfung von Pferden mit inaktivierten Mikroorganismen oder antigenem Material | |
| DE1617545C2 (de) | Verwendung von informatorischer Ribonucleinsäure als Vaccine | |
| DE2713371C2 (enrdf_load_stackoverflow) | ||
| DE3636826A1 (de) | Varicella-zoster-immunglobulin mit hohem titer fuer eine intravenoese verabreichung | |
| DE69420970T2 (de) | Impfstoff zubereitungen | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| CH616959A5 (enrdf_load_stackoverflow) | ||
| CH630807A5 (de) | Verfahren zur herstellung eines antiserums. | |
| DE69127975T2 (de) | Impfstoffe | |
| DE69116155T2 (de) | Neuramidase und glulaktoseoxidase als vaccinadjuvans | |
| EP1265631B1 (de) | Verfahren zur herstellung von vakzinen die eine hitzebehandelte mischung von zumindest einem antigen mit zumindest einem adjuvans enthält | |
| DE191752C (enrdf_load_stackoverflow) | ||
| DE2805311A1 (de) | Respiratorische synzytial-vakzine | |
| DE1966436C3 (de) | Verwendung einer Antigen-Immunserum-Kombination als Impfstoff | |
| DE2340911A1 (de) | Tetanus-antigen und verfahren zu seiner herstellung | |
| DE1902590C2 (de) | Verwendung einer Immunribonucleinsäure (IRNS) zum Immunisieren lebender Tiere | |
| DE1617288C (de) | Verfahren zur Herstellung eines Grippe virusimpfstoffs | |
| DE1021128B (de) | Verfahren zur Herstellung eines Impfstoffes gegen die Rhinotracheitis der Rinder | |
| DE19655440B4 (de) | Verfahren zur Herstellung eines Influenzaimpfstoffs | |
| DE2157148A1 (de) | Immunisierungsmittel, verfahren zur herstellung und seine verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8125 | Change of the main classification |
Ipc: A61K 31/675 |
|
| 8181 | Inventor (new situation) |
Free format text: ERFINDER IST ANMELDER |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |